Juvensis Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $13.8M

  • Investors
  • 9

Juvensis Therapeutics General Information

Description

Developer of gene therapy drugs designed for the treatment of degenerative diseases. The company's technology leverages proprietary telomere regulation to block mitochondrial dysfunction and drive gene therapy innovation, providing healthcare providers with therapeutic solutions for cardiovascular, neurological, and renal conditions.

Contact Information

Formerly Known As
Zhejiang Juvensis Therapeutics, Zhejiang Yufang Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 2211, Building R02, Lane 88, Zhangjiang Road
  • China (China Pilot Free Trade Zone)
  • Shanghai
  • China
+86 025
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Vertical(s)
Corporate Office
  • Room 2211, Building R02, Lane 88, Zhangjiang Road
  • China (China Pilot Free Trade Zone)
  • Shanghai
  • China
+86 025

Juvensis Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Juvensis Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 15-Feb-2025 $13.8M Completed Generating Revenue
4. Early Stage VC 20-May-2024 Completed Generating Revenue
3. Secondary Transaction - Private 07-Mar-2024 Completed Generating Revenue
2. Early Stage VC 29-Jul-2022 Completed Generating Revenue
1. Seed Round 15-Oct-2021 Completed Startup
To view Juvensis Therapeutics’s complete valuation and funding history, request access »

Juvensis Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Juvensis Therapeutics Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jiangbei Investment Group Growth/Expansion Minority
ZhongMei Capital Venture Capital Minority
Hunt Best Capital Venture Capital Minority
Nanjing Jiangbei New Area Innovation Investment Fund Management PE/Buyout Minority
Shanghai Guofang Private Equity Fund Management Growth/Expansion Minority
You’re viewing 5 of 9 investors. Get the full list »

Juvensis Therapeutics FAQs

  • When was Juvensis Therapeutics founded?

    Juvensis Therapeutics was founded in 2021.

  • Where is Juvensis Therapeutics headquartered?

    Juvensis Therapeutics is headquartered in Shanghai, China.

  • What is the size of Juvensis Therapeutics?

    Juvensis Therapeutics has 4 total employees.

  • What industry is Juvensis Therapeutics in?

    Juvensis Therapeutics’s primary industry is Drug Discovery.

  • Is Juvensis Therapeutics a private or public company?

    Juvensis Therapeutics is a Private company.

  • What is Juvensis Therapeutics’s current revenue?

    The current revenue for Juvensis Therapeutics is .

  • How much funding has Juvensis Therapeutics raised over time?

    Juvensis Therapeutics has raised $13.8M.

  • Who are Juvensis Therapeutics’s investors?

    Jiangbei Investment Group, ZhongMei Capital, Hunt Best Capital, Nanjing Jiangbei New Area Innovation Investment Fund Management, and Shanghai Guofang Private Equity Fund Management are 5 of 9 investors who have invested in Juvensis Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process